PRESS RELEASE published on 08/06/2024 at 21:04, 2 years ago EQS-Adhoc: Evotec SE provides guidance update Evotec SE refines guidance for fiscal year 2024, expecting revenue and EBITDA adjustments due to slower sales conversion and margin pressures, focusing on sustainable growth EBITDA Revenue Evotec SE Sustainable Growth Guidance Update
BRIEF published on 07/10/2024 at 07:35, 2 years 1 month ago Evotec and Pfizer Collaborate to Advance Drug Discovery in France Drug Discovery Metabolic Diseases Evotec Pfizer Infectious Diseases
BRIEF published on 07/10/2024 at 07:35, 2 years 1 month ago Evotec et Pfizer collaborent pour faire progresser la découverte de médicaments en France Maladies Métaboliques Evotec Découverte De Médicament Pfizer Maladies Infectieuses
PRESS RELEASE published on 07/10/2024 at 07:30, 2 years 1 month ago Evotec and Pfizer collaborate to advance drug discovery in France Evotec SE collaborates with Pfizer to focus on early discovery research for metabolic and infectious diseases in France. The multi-year agreement includes research support and potential milestones Drug Discovery Evotec SE France Pfizer Metabolic And Infectious Diseases
BRIEF published on 07/08/2024 at 14:05, 2 years 1 month ago Just – Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz Partnership Biosimilars Evotec Sandoz Biologics
BRIEF published on 07/08/2024 at 14:05, 2 years 1 month ago Just – Evotec Biologics étend son partenariat technologique pour les biosimilaires avec Sandoz Partenariat Evotec Biosimilaires Produits Biologiques Sandoz
PRESS RELEASE published on 07/08/2024 at 14:00, 2 years 1 month ago Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz Evotec SE's biologics segment, Just - Evotec Biologics, expands partnership for biosimilars with Sandoz, securing long-term commercial supply. Collaboration aims for cost-efficient development Evotec SE Biosimilars Just - Evotec Biologics Sandoz Commercial Supply
BRIEF published on 06/25/2024 at 07:35, 2 years 1 month ago Just-Evotec Biologics Selected by U.S. DOD for Manufacturing Optimization Evotec SE Biologics Manufacturing U.S. Department Of Defense Monoclonal Antibodies Medical Countermeasures
BRIEF published on 06/25/2024 at 07:35, 2 years 1 month ago Just-Evotec Biologics sélectionné par le DOD américain pour l'optimisation de la fabrication Evotec SE Fabrication De Produits Biologiques Département Américain De La Défense Des Anticorps Monoclonaux Contre-mesures Médicales
PRESS RELEASE published on 06/25/2024 at 07:30, 2 years 1 month ago Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program Just \/ Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program. Evotec SE subsidiary chosen for $39m accelerated mAb development project Evotec SE Just - Evotec Biologics U.S. Department Of Defense Manufacturing Optimization Program MAb Development
Published on 08/19/2026 at 07:00, 25 minutes ago Caldwell Strengthens Life Sciences and Healthcare Practice with Addition of Olga Kozlova in Dubai
Published on 08/19/2026 at 04:00, 3 hours 25 minutes ago Momenta, XHEART, and QNX Build an Autonomous Driving Platform Certified to Global Safety Standards
Published on 08/18/2026 at 23:10, 8 hours 15 minutes ago Secure Blockchain Signs Agreement to Sell Delivery Trust(R) Business
Published on 08/18/2026 at 19:45, 11 hours 40 minutes ago ECC Ventures 5 Corp. Enters Into Business Combination Agreement with Bayrock Resources for Qualifying Transaction
Published on 08/18/2026 at 18:30, 12 hours 55 minutes ago Sterling Metals Announces Approval of Arrangement by QcX Gold Shareholders
Published on 08/19/2026 at 07:00, 25 minutes ago Straumann Group delivers strong second-quarter performance and confirms upgraded profitability outlook for 2026
Published on 08/19/2026 at 07:00, 25 minutes ago DocMorris with strong growth momentum in Rx and Digital Services in the first half of the year and guidance increase
Published on 08/19/2026 at 07:00, 25 minutes ago HomeToGo delivers strong H1 2026: IFRS Revenues increased by 72% to €160.1M as Free Cash Flow soared to €48.2M. FY/26 guidance reaffirmed
Published on 08/18/2026 at 18:00, 13 hours 25 minutes ago KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 13 hours 40 minutes ago Mise à disposition du rapport financier annuel 2025-26
Published on 08/18/2026 at 11:15, 20 hours 9 minutes ago GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 10 au 14 août 2026
Published on 08/18/2026 at 11:15, 20 hours 9 minutes ago GUILLEMOT CORPORATION | Weekly report share buyback from August 10 to August 14 2026
Published on 08/17/2026 at 19:45, 1 day 11 hours ago Aéroports de Paris S.A - July 2026 traffic figures
